Geneuro SA is a leading biopharmaceutical company committed to pioneering innovative treatments for neurological disorders. The company values a patient-centric approach, scientific excellence, and collaboration with global partners. Geneuro SA's corporate philosophy revolves around developing cutting-edge therapies that address significant unmet medical needs while maintaining the highest standards of ethical conduct and accountability. By leveraging their expertise in neuroscience, Geneuro SA aims to improve patients' lives and contribute to the advancement of medical science. As a renowned player in the pharmaceutical industry, Geneuro SA continually strives for excellence in research, development, and commercialization to make a lasting impact on the field of neurology.

Geneuro SA is primarily present in Switzerland and France.

Geneuro SA has achieved several significant milestones in its history. One notable accomplishment is the successful completion of clinical trials for GNbAC1, a monoclonal antibody targeting multiple sclerosis (MS). The company has also secured numerous partnerships and collaborations with leading pharmaceutical companies, strengthening its research and development activities. Furthermore, Geneuro SA has obtained several patents for its innovative technologies and therapeutic candidates. These achievements demonstrate the company's dedication to advancing the treatment options for MS and other neurological diseases. Geneuro SA's commitment to scientific excellence and strategic collaborations has positioned it as a leading player in the field of neurology research.

Geneuro SA is a renowned biopharmaceutical company headquartered in Geneva, Switzerland. Founded in [year], Geneuro SA focuses on developing innovative therapies for the treatment of neurological and autoimmune disorders. With a strong commitment to tackling diseases such as multiple sclerosis, Geneuro SA has made significant strides in understanding the role of viral pathogens in these conditions. By employing their proprietary technology, the company aims to revolutionize the treatment landscape. Geneuro SA has a team of dedicated experts with extensive experience in clinical research and drug development, making it a trusted player in the pharmaceutical industry.

The main competitors of Geneuro SA in the market are companies such as Biogen, Novartis, Sanofi, and Roche.

Geneuro SA is primarily active in the pharmaceutical and healthcare industries. With a focus on developing therapeutic solutions, Geneuro SA utilizes innovative technologies to address neurological disorders. As a leading company in the field, Geneuro SA strives to advance treatment options for conditions such as multiple sclerosis and various autoimmune diseases. Through its extensive research and collaborations, Geneuro SA seeks to improve patients' quality of life and bring about significant advancements in the pharmaceutical sector.

The business model of Geneuro SA revolves around developing and commercializing innovative therapies for the treatment of autoimmune diseases. The company focuses on targeting pathogenic proteins involved in the immune system dysfunctions, particularly those associated with Multiple Sclerosis (MS) and other neurological disorders. Geneuro SA utilizes its proprietary technology, called Temelimab, which acts as a monoclonal antibody to neutralize the disease-causing proteins. By investing in research and development, Geneuro SA aims to provide effective and safe treatment options for patients suffering from these autoimmune diseases.

Az Geneuro P/E mutatója -0,34.

Az Geneuro KUV 0.

Az AlleAktien Minőségi Score Geneuro esetében 4/10.

A Geneuro esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Geneuro nyereség -12,33 Mió. EUR.

Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Switzerland. It was founded in 2007 with the goal of developing novel therapy options for autoimmune diseases. The company specializes in the discovery and development of antibody therapies against the Multiple Sclerosis associated Retrovirus (MSRV). Geneuro SA is divided into three main areas: research and development, production, and distribution. The company provides its discoveries and patents to licensed pharmaceutical companies and also conducts its own clinical studies to gather information on their antibody therapies. The research and development program of Geneuro SA focuses on finding innovative solutions for the treatment of autoimmune diseases, particularly Multiple Sclerosis (MS). MS is a chronic degenerative disease of the central nervous system caused by inflammation and damage to the myelin sheath surrounding nerve fibers. According to the Multiple Sclerosis International Federation (MSIF), more than 2.5 million people worldwide suffer from MS. Geneuro's most well-known product is GNbAC1, an antibody against the Multiple Sclerosis associated Retrovirus (MSRV), a virus associated with Multiple Sclerosis. GNbAC1 is the first specific antibody therapy against MSRV to be tested in clinical trials. It is designed to slow down the progression of MS by stopping the infection by MSRV. In addition to MS, Geneuro SA also researches the application of GNbAC1 in other autoimmune diseases such as dermatomyositis and ALS. The company operates an integrated quality management system that ensures all products and processes comply with international FDA and EMA guidelines. Production is carried out in collaboration with qualified contract manufacturers. Geneuro SA's distribution strategy focuses on collaboration with leading pharmaceutical companies. The company has already entered into several licensing agreements with international pharmaceutical companies including Merck Serono, Servier, and Mitsubishi Tanabe Pharma. Overall, Geneuro SA offers a promising approach in medical research with its innovative antibody therapies against autoimmune diseases. The focus on collaboration with large pharmaceutical companies also provides long-term growth potential.

A(z) Geneuro évente alkalommal oszt ki 0 EUR összegű osztalékot.

A Geneuro esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Geneuro ISIN kódja: CH0308403085.

A Geneuro WKN-je A2AHDP.

Az Geneuro tőzsdei rövidítése GNRO.PA.

Az elmúlt 12 hónapban a(z) Geneuro osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Geneuro várhatóan 0 EUR összegű osztalékot fog fizetni.

A(z) Geneuro jelenlegi osztalékhozama .

A(z) Geneuro negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Geneuro az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 EUR összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Geneuro a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Geneuro által 2024. 07. 08.-án/én fizetett 0 EUR összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 07. 08.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 07. 08. időpontban történt.

2023 évben a Geneuro 0 EUR összegű osztalékot fizetett ki.

Az Geneuro osztalékait EUR fizeti ki.